KLOW Peptide
Cyan-on-off-black blueprint exploded-view of the four KLOW peptide nodes — a teal KPV chain, a cyan GHK-Cu lattice, an indigo BPC-157 ribbon and a sky-blue TB-500 bracket — wired to a central assembly callout, with one node left as an empty dashed outline marking the missing blend data

RESEARCH DIGEST // FOUR-PEPTIDE BLEND

KLOW peptide is a four-node research blend wired from the KPV, GHK-Cu, BPC-157 and TB-500 literature

Component findings summarized from the peer-reviewed record. No controlled blend trial exists. One honest gap drawn into the schematic.

Open the schematicRead the record

In plain English

KLOW peptide is not a single molecule. It is a research blend of four separate peptides — KPV, GHK-Cu, BPC-157 and TB-500 — co-dissolved in one vial. Each of the four has its own published research record. None of the four is FDA-approved for human use. And the four-peptide blend itself has never been tested in any controlled study. That last point matters: any claim that the combination does more than each peptide alone is an extrapolation, not a finding.

The research community uses the blend for recovery and repair contexts — mainly connective tissue, inflammation and wound healing. The component studies support this direction. TB-500 (or rather the related full-length protein thymosin beta-4) accelerated wound closure by 42% at four days in a rat model [1]. BPC-157 accelerated tendon repair in rats across biomechanical and functional measures [2]. KPV suppressed inflammatory signaling in gut epithelial cells [3]. GHK-Cu drove matrix synthesis and gene-expression shifts in fibroblasts [4].

What people report from the blend — and what to watch for — is on the effects page.

What is KLOW peptide

KLOW peptide is a co-formulated research blend of four chemically distinct peptides. The most common research-vial composition is 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg.

GHK-Cu (glycyl-histidyl-lysine copper complex, CAS 89030-95-5, MW 402.92 Da) is the mass-dominant component at roughly 62.5% of the total. It is a copper-chelated tripeptide (that is, three amino acids bound 1:1 to a copper ion) studied for collagen synthesis, extracellular-matrix remodeling and broad transcriptomic effects in skin fibroblasts.

KPV (lysine-proline-valine, CAS 67727-97-3, MW 342.44 Da) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (the last three amino acids of a 13-residue hormone). It is the anti-inflammatory arm: a substrate of the PepT1 (SLC15A1) transporter (Km ~160 microM) that carries it into inflamed gut and immune cells, where it inhibits NF-kappaB nuclear import and reduces inflammatory cytokine output [3].

BPC-157 (body protection compound 157, CAS 137525-51-0, MW 1419.53 Da) is a synthetic 15-amino-acid peptide derived from a gastric-juice protein. It activates the VEGFR2/PI3K/Akt/eNOS angiogenesis pathway (VEGFR2 is the receptor that initiates new blood-vessel growth) and upregulates the growth-hormone receptor in tendon fibroblasts [2].

TB-500 (Ac-LKKTET-Q, MW 889.02 Da) is an N-acetylated seven-amino-acid fragment of the native 43-residue protein thymosin beta-4. It carries the actin-binding motif of the parent protein. Most foundational efficacy data — including the wound re-epithelialization findings — are for full-length thymosin beta-4, not the short fragment. The distinction matters and is detailed in the blend components page.

KLOW blend

The KLOW peptide blend is a co-formulation, not a chemical complex. The four peptides remain separate molecules in solution; they do not fuse into a single new compound.

The combination rationale is mechanistic: KPV addresses cytokine signaling, GHK-Cu addresses matrix synthesis and copper supply, BPC-157 addresses the angiogenic axis (new blood-vessel formation), and TB-500 / thymosin beta-4 addresses cell migration and re-epithelialization (the closure of the outer tissue layer over a wound). The four arms are theoretically complementary steps in a tissue-repair cascade.

One inherent limitation: the four peptides have markedly different clearance rates. The tripeptides KPV and GHK-Cu clear far faster than BPC-157; and the short TB-500 fragment behaves differently from full-length thymosin beta-4. A single co-formulated dose cannot hold all four at matched exposures — a pharmacokinetic mismatch built into the vial.

KLOW peptide benefits

Component-attributed findings from the single-compound literature. The blend itself has no controlled study.

TB-500 arm (thymosin beta-4): In a rat full-thickness wound model, topical or IP thymosin beta-4 increased re-epithelialization (regrowth of surface tissue) by 42% at four days and up to 61% at seven days versus saline, with increased wound contraction (greater than or equal to 11% by day 7) and raised collagen deposition and angiogenesis. As little as 10 pg stimulated keratinocyte migration two- to three-fold [1]. A separate rodent study documented concurrent angiogenesis, wound healing and hair-follicle effects [12].

BPC-157 arm: Fully transected rat Achilles tendons healed better on biomechanical, functional, microscopic and macroscopic measures with IP BPC-157 (10 microg, 10 ng or 10 pg/rat/day) versus untreated controls; in vitro tendocyte outgrowth was also stimulated [2]. A 2026 review covering BPC-157 for musculoskeletal conditions confirms favorable tissue-repair outcomes in animal models, while noting human safety data remain scarce [7].

GHK-Cu arm: Topical GHK-Cu increased collagen production in 70% of treated women vs 50% for vitamin C and 40% for retinoic acid. Plasma GHK naturally declines from ~200 ng/mL at age 20 to ~80 ng/mL by age 60. In vitro, nanomolar GHK-Cu stimulates procollagen-I, procollagen-IV, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin [4].

KPV arm: Nanomolar KPV reduced NF-kappaB and MAPK activation and pro-inflammatory cytokine secretion in human intestinal epithelial cells and T cells in culture; oral KPV reduced the severity of two chemically induced colitis models in mice [3].

See KLOW effects for what researchers in the community report, clearly labeled as anecdotal.

KLOW vs glow

GLOW and KLOW are distinct blends. GLOW does not contain KPV. KLOW adds KPV as its anti-inflammatory fourth arm — the PepT1-mediated NF-kappaB suppressor [3]. The two blends share the GHK-Cu, BPC-157 and TB-500 components but differ in the fourth position and in total composition. Neither blend has been tested as a combination in any controlled study. WOLVERINE is a separate blend again and is outside the scope of this site.

KLOW peptide blend

The KLOW peptide blend is not a weight-loss or metabolic compound. None of its four components is a GLP-1 receptor agonist (the receptor class behind incretin-based drugs) or an established metabolic or appetite-regulating agent. The blend's research context is tissue repair and inflammation, not weight management. Any vendor framing KLOW as a weight-loss agent is unsupported by the component literature.